Tumour cell-derived IL-1α is a major inducer of Tregs that attracts the chemokine CCL22, and therapeutic blockade of the IL-1 pathway may also be an effective approach to limiting tumour-induced immunosuppression [202]. The gene discussed is IL1B; the disease is neoplasm.